AQST Aquestive Therapeutics, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
AQST Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
Current Price
Live
$3.24
Analyst Target
$8.62
+166.2%
Upside
52W High
$7.55
52W Low
$2.12
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
78%
Analysis Accuracy
The Advanced Deterministic Scorecard reveals severe financial distress with a Piotroski F-Score of just 1/9, indicating weak fundamental health. Despite a strong analyst recommendation of 'strong_buy', the company is unprofitable with negative margins, deteriorating earnings, and insider selling activity. Valuation metrics are stretched relative to peers, while cash flow and equity-based metrics are largely negative or unavailable. The stock trades at a significant premium to any conservative intrinsic value estimate, amplifying downside risk.
Key Strengths
High gross margin of 60.28% suggests strong pricing power or low production costs in core operations
Exceptionally high current and quick ratios (5.93 and 5.51) indicate substantial liquid asset cushion
Analyst consensus is strongly bullish with a $8.62 target price, implying 166% upside
Recent quarterly EPS surprise of +88.3% in Q2 2024 and volatility in earnings suggest potential turnaround catalysts
Low market cap of $0.40B provides potential for high growth if execution improves
Key Risks
Piotroski F-Score of 1/9 signals critical financial weakness and high risk of continued underperformance
Negative profitability across all metrics: ROA of -25.50%, operating margin of -89.63%, and net margin of -158.95%
Forward P/E of -7.28 and Price/Book of -95.29 reflect unprofitability and negative book value, invalidating traditional valuation
Insiders have sold $1.69M in shares over the last 6 months with zero buys, signaling lack of confidence
Revenue declining YoY by 5.40% and inconsistent earnings performance with only 1 beat in last 4 quarters
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare AQST against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning AQST from our newsroom.
Newest → oldest
No matching news yet.